Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: The iron and copper complexes of anthracyclines decrease RNA-binding activity

Molecular Pharmacology

Volumn 62, Issue 4, 2002, Pages 888-900

  Kwok, Juliana C ^a   Richardson, Des R ^a  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACONITATE HYDRATASE; ANTHRACYCLINE ANTIBIOTIC AGENT; CATALASE; CHELATING AGENT; COPPER COMPLEX; DAUNORUBICIN; DEFEROXAMINE; DOXORUBICIN; DOXORUBICINOL; EBSELEN; EPIRUBICIN; FREE RADICAL; IRON COMPLEX; IRON REGULATORY FACTOR; MANGANESE TETRAKIS(4 BENZOIC ACID)PORPHYRIN COMPLEX; MESSENGER RNA; RAZOXANE; SCAVENGER; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; HEART MUSCLE CELL; HUMAN; HUMAN CELL; INCUBATION TIME; IRON CHELATION; IRON METABOLISM; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN RNA BINDING; RAT; TUMOR CELL;

ACONITATE HYDRATASE; ACONITIC ACID; ANTIBIOTICS, ANTINEOPLASTIC; CHELATING AGENTS; COPPER; CYTOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG INTERACTIONS; FREE RADICALS; HEART; HUMANS; IRON; IRON REGULATORY PROTEIN 2; IRON-REGULATORY PROTEINS; IRON-SULFUR PROTEINS; MYOCARDIUM; RNA; RNA-BINDING PROTEINS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0036784362     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.62.4.888     Document Type: Article

References (41)

1. Abboud S and Haile DJ (2000) A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 275:19906-19912.
2. Beinert H and Kennedy MC (1993) Aconitase, a two-faced protein: enzyme and iron regulatory factor. FASEB J 7:1442-1449.
3. Blatt J and Huntley D (1989) Enhancement of in vitro activity against neuroblastoma by doxorubicin and deferoxamine. J Natl Cancer Inst 81:866-870.
4. Chitambar CR and Wereley JP (1995) Effect of hydroxyurea on cellular iron metabolism in human leukemic CCRF-CEM cells: changes in iron uptake and the regulation of transferrin receptor and ferritin gene expression following inhibition of DNA synthesis. Cancer Res 55:4361-4366.
5. DeAtley SM, Aksenov MY, Aksenova MV, Jordan B, Carney JM, and Butterfield DA (1999) Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture. Toxicology 134:51-62.
6. Drapier J-C and Hibbs JB Jr (1996) Aconitases: a class of metalloproteins highly sensitive to nitric oxide synthesis. Methods Enzymol 269:26-36.
7. Gao J and Richardson DR (2001) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents. IV. The mechanisms involved in inhibiting cell cycle progression. Blood 98:842-850.
8. Garnier-Suillerot A (1988) Metal anthracycline and anthracenedione complexes as a new class of anticancer agents, in Anthracyclines and Anthracenedione-Based Anticancer Agents (Lown WJ ed) pp 130-157, Elsevier, Amsterdam.
9. Gerwirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem Pharmacol 57:727-741.
10. Gianni L and Myers C (1992) The role of free radical formation in the cardiotoxicity of anthracyclines, in Cancer Treatment and the Heart (Muggia FM, Green MD, and Speyer JL eds) pp 9-46, Johns Hopkins University Press, Baltimore.
11. Gianni L, Vigano L, Lanzi C, Niggler M, and Malatesta V (1988) Role of daunosamine and hydroacetyl side chain in reaction with iron and lipid peroxidation by anthracyclines. J Natl Cancer Inst 80:1104-1111.
12. Goncharova EJ, Kam Z, and Geiger B (1992) The involvement of adherens junction components in myofibrillogenesis in cultured cardiac myocytes. Development (Camb) 114:173-183.
13. Guo B, Brown FM, Phillips JD, Yu Y, and Leibold EA (1995) Characterization and expression of iron regulatory protein 2 (IRP2). Presence of multiple IRP2 transcripts regulated by intracellular iron levels. J Biol Chem 270:16529-16535.
14. Hentze MW and Kühn LC (1996) Molecular control of vertebrate iron metabolism: mRNA based regulatory circuits operated by iron, nitric oxide and oxidative stress. Proc Natl Acad Sci USA 93:8175-8182.
15. Herman EH, Zhang J, and Ferrans VJ (1994) Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats. Cancer Chemother Pharmacol 35:93-100.
16. Hershko C, Link G, Tzahor M, Kaltwasser JP, Athias P, Grynberg A, and Pinson A (1993) Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture. J Lab Clin Med 122:245-251.
17. Hescheler J, Meyer R, Plant S, Krautwurst D, Rosenthal W, and Schultz G (1991) Morphological, biochemical and electrophysiological characterization of a clonal cell (H9c2) line from rat heart. Circ Res 69:1476-1486.
18. Hirling H, Henderson BR, and Kühn LC (1994) Mutational analysis of the [4Fe-4S] cluster converting iron regulatory factor from its RNA-binding form to cytoplasmic aconitase. EMBO (Eur Mol Biol Organ) J 13:453-461.
19. Konorev EA, Kennedy MC, and Kalyanaraman B (1999) Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: the role of reactive oxygen and nitrogen intermediates. Arch Biochem Biophys 368:421-428.
20. Kotamraju S, Chitambar CR, Kalivendi SV, Joseph J, and Kalyanaraman B (2002) Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells-role of oxidant-induced iron signaling in apoptosis. J Biol Chem 277:17179-17187.
21. Leibold EA and Munro HN (1988) Cytoplasmic protein binds in vitro to a highly conserved sequence in the 5′ untranslated region of ferritin heavy- and light-subunit mRNAs. Proc Natl Acad Sci USA 85:2171-2175.
22. Link G, Pinson A, and Hershko C (1985) Heart cells in culture: a model of myocardial iron overload and chelation. J Lab Clin Med 106:147-153.
23. Link G, Tirosh R, Pinson A, and Hershko C (1996) Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron anthracycline interaction. J Lab Clin Med 127:272-278.
24. Minotti G, Cavaliere AF, Mordente A, Rossi M, Schiavello R, Zamparelli R, and Possati G (1995) Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. J Clin Investig 95:1595-1605.
25. Minotti G, Recalcati S, Mordente A, Liberi G, Calafiore AM, Mancuso C, Preziosi P, and Cairo G (1998) The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 cytosolic fractions from human myocardium. FASEB J 12:541-552.
26. Minotti G, Ronchi R, Salvatorelli E, Menna P, and Cairo G (2001) Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res 61:8422-8428.
27. Muindi JRF, Sinha BK, and Myers CE (1984) Hydroxyl radical production and DNA damage induced by anthracycline iron complex. FEBS Lett 172:226-230.
28. Oshiro S, Nozawa K, Hori M, Zhang C, Hashimoto Y, Kitajima S, and Kawamura K (2002) Modulation of iron regulatory protein-1 by various metals. Biochem Biophys Res Commun 290:213-218.
29. Philpott CC, Haile D, Rouault TA, and Klausner RD (1993) Modification of a free Fe-S cluster cysteine residue in the active iron-responsive element-binding protein prevents RNA binding. J Biol Chem 268:17655-17658.
30. Richardson DR and Baker E (1992a) Intermediate steps in cellular iron uptake from transferrin. Detection of a cytoplasmic pool of iron free of transferrin. J Biol Chem 267:21384-21389.
31. Richardson DR and Baker E (1992b) Two mechanisms of iron uptake from transferrin by melanoma cells. The effect of desferrioxamine and ferric ammonium citrate. J Biol Chem 267:13972-13979.
32. Richardson DR and Milnes K (1997) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. II. The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood 89:3025-3038.
33. Richardson DR, Tran E, and Ponka P (1995) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents. Blood 86:4295-4306.
34. Saad SY, Najjar TA, and Al-Rikabi AC (2001) The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol Res 43:211-218.
35. Sawyer DB, Fukazawa R, Arstall MA, and Kelly RA (1999) Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res 84:257-265.
36. Shiloh J, Iancu TC, Bauminger ER, Link G, Pinson A, and Hershko C (1992) Deferoxamine induced iron mobilization and redistribution of myocardial iron in cultured rat heart cells: studies of the chelatable iron pool by electron microscopy and Mossbauer spectroscopy. J Lab Clin Med 119:429-437.
37. Takanashi S and Bachur NR (1976) Adriamycin metabolism in man. Evidence from urinary metabolites. Drug Metab Dispos 4:79-87.
38. Terman A and Brunk UT (1998) On the degradability and exocytosis of ceroid/ lipofuscin in cultured rat cardiac myocytes. Mech Ageing Dev 100:145-156.
39. Theil EC and Eisenstein RS (2000) Combinatorial mRNA regulation: iron regulatory proteins and iso-iron-responsive elements (Iso-IREs). J Biol Chem 275:40659-40662.
40. Wardrop SL, Watts RN, and Richardson DR (2000) Nitrogen monoxide activates iron regulatory protein 1 RNA-binding activity by two possible mechanisms: effect on the [4Fe-4S] cluster and iron mobilization from cells. Biochemistry 39:2748-2758.
41. Weiss G, Kastner S, Brock J, Thaler J, and Grunewald K (1997) Modulation of transferrin receptor expression by dexrazoxane (ICRF-187) via activation of iron regulatory protein. Biochem Pharmacol 53:1419-1424.